Late-Stage Therapeutic Options in Lung Cancer

FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.

Reviewing OPAL Results in EGFR+ NSCLC Before Phase 3 FLAURA2 Presentation

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.

Ways to Manage Toxicities Related to Osimertinib for Lung Cancer

Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.

Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC

Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.

Overview of Available Therapies for EGFR Mutations in Lung Cancer

Mark A. Socinski, MD, discusses types of EGFR mutations in non–small cell lung cancer and the treatments that target these mutations.

Approaching Treatment for a Patient With NSCLC and an EGFR Mutation

During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.

Expert Compares Atezolizumab and Durvalumab as Therapy for ES-SCLC

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

Sequencing Osimertinib in Patients With EGFR-Mutated NSCLC

Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.

Frontline Targeted Options for EGFR-Mutated NSCLC

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Atezolizumab and Durvalumab Show Similar Benefit for ES-SCLC

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

Approaches and Obstacles to Frontline Treatment for Small Cell Lung Cancer

During a live virtual event, Melissa L. Johnson, MD, discussed how to treat a 73-year-old patient who was recently diagnosed with extensive-stage small cell lung cancer.